{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:24:31Z","timestamp":1792175071881,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA021765"],"award-info":[{"award-number":["CA021765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.radonc.2019.01.026","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T14:19:00Z","timestamp":1549376340000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy"],"prefix":"10.1016","volume":"134","author":[{"given":"Christopher L.","family":"Tinkle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle L.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue C.","family":"Kaste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry L.","family":"Shulkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee C.","family":"Talleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie E.","family":"Flerlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika L.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Krasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2019.01.026_b0005","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/bmt.2008.278","article-title":"Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma","volume":"42","author":"Claviez","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.radonc.2019.01.026_b0010","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.semradonc.2007.02.009","article-title":"Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity","volume":"17","author":"Hodgson","year":"2007","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0015","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2019.01.026_b0020","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2019.01.026_b0025","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1200\/JCO.2005.07.930","article-title":"Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL\/GPOH-HD study group","volume":"23","author":"Schellong","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0030","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.2008.20.3778","article-title":"Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a Children's Oncology Group report","volume":"27","author":"Cole","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/pbc.25205","article-title":"Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory\/relapsed Hodgkin lymphoma, AHOD00P1: a Children's Oncology Group report","volume":"62","author":"Trippett","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.radonc.2019.01.026_b0040","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2019.01.026_b0045","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oxfordjournals.annonc.a058128","article-title":"Salvage radiotherapy in recurrent Hodgkin's disease","volume":"3","author":"Brada","year":"1992","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0055","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0360-3016(93)90460-D","article-title":"Radiation therapy salvage of Hodgkin's disease following chemotherapy failure","volume":"27","author":"Leigh","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.01.026_b0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.1987.5.1.38","article-title":"Radiation therapy salvage of Hodgkin's disease following chemotherapy failure","volume":"5","author":"Fox","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0065","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19930701)72:1<207::AID-CNCR2820720137>3.0.CO;2-A","article-title":"Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy","volume":"72","author":"Uematsu","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2019.01.026_b0070","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.1987.5.4.550","article-title":"Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease","volume":"5","author":"Roach","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0360-3016(95)00180-7","article-title":"Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed\/refractory Hodgkin's disease","volume":"33","author":"Mundt","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.01.026_b0080","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/annonc\/mdm287","article-title":"Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma","volume":"18","author":"Macdonald","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0167-8140(94)01502-T","article-title":"Involved field radiation therapy for Hodgkin's disease autologous bone marrow transplantation regimens","volume":"34","author":"Pezner","year":"1995","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0090","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ijrobp.2017.01.222","article-title":"Accelerated total lymphoid irradiation-containing salvage regimen for patients with refractory and relapsed hodgkin lymphoma: 20 years of experience","volume":"97","author":"Rimner","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.01.026_b0095","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/bjc.1992.426","article-title":"Outcome of children with resistant and relapsed Hodgkin's disease","volume":"66","author":"James","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2019.01.026_b0100","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1002\/cncr.25225","article-title":"Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients","volume":"116","author":"Metzger","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2019.01.026_b0105","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/JCO.2006.10.1386","article-title":"Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin\u2019s lymphoma","volume":"25","author":"Sieniawski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0110","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/00043426-200411000-00010","article-title":"Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease","volume":"26","author":"Stoneham","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0115","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1200\/JCO.2004.02.121","article-title":"High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices","volume":"22","author":"Lieskovsky","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0120","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/bmt.2009.197","article-title":"High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma","volume":"45","author":"Akhtar","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.radonc.2019.01.026_b0125","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbmt.2010.07.002","article-title":"Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962","volume":"17","author":"Harris","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.radonc.2019.01.026_b0130","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3109\/10428190903580410","article-title":"Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution","volume":"51","author":"Shafer","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.radonc.2019.01.026_b0135","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2141.2012.09199.x","article-title":"Outcome of children and adolescents with recurrent\/refractory classical Hodgkin lymphoma, a study from the Societe Francaise de Lutte Contre le Cancer des Enfants et des Adolescents (SFCE)","volume":"158","author":"Gorde-Grosjean","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.radonc.2019.01.026_b0140","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/pbc.24851","article-title":"Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma","volume":"61","author":"Harker-Murray","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.radonc.2019.01.026_b0145","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.2012.5847","article-title":"Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma","volume":"307","author":"Metzger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2019.01.026_b0150","unstructured":"Flerlage J (2006). Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma. ClinicalTrials.gov Identifier: NCT00352027. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00352027?id=NCT00846742+OR+NCT00352027&rank=2&load=cart."},{"key":"10.1016\/j.radonc.2019.01.026_b0155","unstructured":"Rubnitz J (2009). Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma. ClinicalTrials.gov Identifier: NCT00846742. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00846742?id=NCT00846742+OR+NCT00352027&rank=1&load=cart."},{"key":"10.1016\/j.radonc.2019.01.026_b0160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2307\/2530374","article-title":"The analysis of failure times in the presence of competing risks","volume":"34","author":"Prentice","year":"1978","journal-title":"Biometrics"},{"key":"10.1016\/j.radonc.2019.01.026_b0165","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1164\/ajrccm\/146.2.485","article-title":"Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation","volume":"146","author":"Jules-Elysee","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.radonc.2019.01.026_b0170","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory hodgkin lymphoma","volume":"99","author":"Wilke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.01.026_b0175","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2010.05.010","article-title":"Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed\/refractory Hodgkin lymphoma?","volume":"81","author":"Kahn","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.01.026_b0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(96)00277-5","article-title":"High-dose therapy and autologous bone marrow transplantation for relapsed\/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival","volume":"36","author":"Poen","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.01.026_b0185","first-page":"1","article-title":"Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience","author":"Giulino-Roth","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.radonc.2019.01.026_b0190","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0360-3016(97)00352-0","article-title":"Salvage radiotherapy for Hodgkin's disease following chemotherapy failure","volume":"39","author":"Wirth","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.01.026_b0195","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00253147","article-title":"Combined chemotherapy-radiotherapy approach in locally advanced (T3b\u2013T4) breast cancer","volume":"1","author":"De Lena","year":"1978","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.radonc.2019.01.026_b0200","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/1097-0142(19840901)54:5<811::AID-CNCR2820540508>3.0.CO;2-E","article-title":"Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck","volume":"54","author":"Ensley","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2019.01.026_b0205","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/0360-3016(90)90303-2","article-title":"Relation between responses to induction chemotherapy and subsequent radiotherapy in advanced or multicentric squamous cell carcinomas of the head and neck","volume":"18","author":"Panis","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.01.026_b0210","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/10428190310001646022","article-title":"Prognostic factors in Hodgkin's disease","volume":"45","author":"Provencio","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.radonc.2019.01.026_b0215","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2019.01.026_b0220","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1200\/JCO.1993.11.11.2243","article-title":"Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry","volume":"11","author":"Williams","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2019.01.026_b0225","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2019.01.026_b0230","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1182\/blood-2012-03-418673","article-title":"Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2019.01.026_b0235","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814019300532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814019300532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T08:02:37Z","timestamp":1571299357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814019300532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":47,"alternative-id":["S0167814019300532"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2019.01.026","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2019.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}